HLA-E基因表达沉默对人乳腺癌细胞生物学行为的影响

doi:10.3969/j.issn.1004-616x.2023.01.003

Abstract

Abstract: OBJECTIVE: To investigate the expression of HLA-E gene in human breast cancer cells and its effect on rates of proliferation，apoptosis，invasion and migration of breast cancer cells，and analyze the feasibility of siRNA (small interfering RNA) silencing of HLA-E as gene therapy. METHODS: Specific siRNA sequences of HLA-E gene were designed and synthesized，and the sequences were transfected into human breast cancer cells MDA-MB-231 with liposome Vigofect. For comparisons，blank control，negative control and liposome groups were established. Quantitative real-time PCR and Western blot were used to detect HLA-E mRNA and protein expression. CCK-8 and flow cytometry were used to detect proliferation and apoptosis rates of the cancer cells. Transwell assay was used to detect the invasion and migration. RESULTS: After transfection with HLA-E siRNA，gene and protein expressions of HLA-E in the cancer cells were reduced significantly compared with the control groups. In addition， proliferation rates of the transfected cancer cells were significantly decreased (P<0.01)，apoptosis rates were significantly increased (P<0.01) while invasion and migration were significantly decreased (P<0.01). CONCLUSION: siRNA targeting of HLA-E effectively suppressed its expression in the breast cancer cells together with inhibition of their proliferation， induction of apoptosis， and reduction of migration and invasion.

Key words: HLA-E gene, breast cancer, small interfering RNA, gene therapy

CLC Number:

WU Zhencun, ZHOU Yan. Effect of HLA-E gene silencing on biological behavior of breast cancer cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 15-20.

References

[1] EMENS L A. Breast cancer immunotherapy:facts and hopes[J]. Clin Cancer Res, 2018, 24(3):511-520.
[2] BASU A, RAMAMOORTHI G, JIA Y, et al. Immunotherapy in breast cancer:current status and future directions[J]. Adv Cancer Res, 2019, 143:295-349.
[3] SHEIKH-HOSSEINI M, LARIJANI B, GHOLIPOOR KAKROODI Z, et al. Gene therapy as an emerging therapeutic approach to breast cancer:new developments and challenges[J]. Hum Gene Ther, 2021, 32(21/22):1330-1345.
[4] 郭智慧, 周庆, 蒋安科, 等. 小干扰RNA技术对沉默乳腺细胞中DEK基因的表达及乳腺癌细胞增殖与凋亡的影响[J]. 中国妇幼保健, 2018, 33(14):3307-3310.
[5] 管海涛, 薛兴欢, 王西京, 等. 靶向survivin的siRNA抑制乳腺癌MCF-7细胞增殖并诱导其凋亡[J]. 中华肿瘤杂志, 2006, 28(5):326-330.
[6] 周艳, 吴振村, 唐玉红, 等. HLA-E基因多态性及血浆可溶性HLA-E水平与乳腺癌遗传易患性的关系[J]. 细胞与分子免疫学杂志, 2015, 31(4):524-527.
[7] 周艳, 吴振村, 程健君, 等. 人类白细胞抗原-E基因多态性与乳腺癌遗传易感性的关系[J]. 肿瘤防治研究, 2015, 42(2):190-193.
[8] SZEKELY B, BOSSUYT V, LI X, et al. Immunological differences between primary and metastatic breast cancer[J]. Ann Oncol, 2018, 29(11):2232-2239.
[9] KANEVSKIY L, EROKHINA S, KOBYZEVA P, et al. Dimorphism of HLA-E and its disease association[J]. Int J Mol Sci, 2019, 20(21):5496.
[10] SHARPE H R, BOWYER G, BRACKENRIDGE S, et al. HLA-E:exploiting pathogen-host interactions for vaccine development[J]. Clin Exp Immunol, 2019, 196(2):167-177.
[11] DA SILVA, SILVA T G A, DUARTE R A, et al. Expression of the classical and nonclassical HLA molecules in breast cancer[J]. Int J Breast Cancer, 2013, 2013:250435.
[12] DE KRUIJF E M, SAJET A, VAN NES J G H, et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients[J]. J Immunol, 2010, 185(12):7452-7459.
[13] TALEBIAN YAZDI M, VAN RIET S, VAN SCHADEWIJK A, et al. The positive prognostic effect of stromal CD8⁺ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma[J]. Oncotarget, 2016, 7(3):3477-3488.
[14] HIRAOKA N, INO Y, HORI S, et al. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients[J]. Cancer Sci, 2020, 111(8):3057-3070.
[15] HUANG R X, ZHANG D Y, LI F, et al. Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells[J]. Oncol Lett, 2017, 13(5):3379-3386.
[16] ÖZGÜL ÖZDEMIR R B, OZDEMIR A T, OLTULU F, et al. A comparison of cancer stem cell markers and nonclassical major histocompatibility complex antigens in colorectal tumor and noncancerous tissues[J]. Ann Diagn Pathol, 2016, 25:60-63.
[17] SINGH A, TRIVEDI P, JAIN N K. Advances in siRNA delivery in cancer therapy[J]. Artif Cells Nanomed Biotechnol, 2018, 46(2):274-283.
[18] LI C F, CAO S, LIU Z, et al. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells[J]. Int J Cancer, 2010, 127(7):1507-1516.
[19] CHEN Y C, STAMATOYANNOPOULOS G, SONG C Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro[J]. Cancer Res, 2003, 63(16):4801-4804.
[20] LAPTEVA N, YANG A G, SANDERS D E, et al. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo[J]. Cancer Gene Ther, 2005, 12(1):84-89.
[21] YHEE J Y, SONG S Y, LEE S J. et al. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance[J]. J Control Release, 2015, 198:1-9.

Effect of HLA-E gene silencing on biological behavior of breast cancer cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.
[2]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[3]	FAN Xiaojie, LI Qingjing, GU Lina, SANG Meixiang, SHAN Baoen. Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 184-191.
[4]	XIN Yumeng, LIANG Huanxi, SUN Zhenxiao. Effectiveness of licorice and dried ginger decoction against mouse breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 88-92.
[5]	GUO Xiaojuan, WANG Jinxi, NIU Guangxu, TIAN Yunxiao. Expression and correlation analyses of EGFR and HER-2 in different types of breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 119-123,148.
[6]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[7]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[8]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[9]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[10]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[11]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[12]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[13]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[14]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[15]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.